Syntaxin raises £3m from Abingworth

Syntaxin Ltd, a newly formed biopharmaceutical company focussing on the discovery and development of new medicines for the treatment of neurological, respiratory and metabolic diseases, has been launched as the first spin-out from the UK Health Protection Agency (HPA).